国际肿瘤学杂志

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (9): 562-565.doi: 10.3760/cma.j.issn.1673-422X.2019.09.011

• 综述 • 上一篇    下一篇

转化生长因子-β通路与卵巢癌靶向治疗

唐南敏1,于占彩2   

  1. 1四川省隆昌市人民医院妇产科642150； 2山东省威海市立医院肿瘤科264200
  • 收稿日期:2019-07-11 出版日期:2019-09-08 发布日期:2019-09-08
  • 通讯作者: 于占彩 E-mail:lzg6598@126.com

Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer

Tang Nanmin1, Yu Zhancai2   

  1. 1Department of Gynaecology and Obstetrics, People′s Hospital of Longchang City, Sichuan Province, Longchang 642150, China; 2Department of Oncology, Weihai Municipal Hospital, Shandong Province, Weihai 264200, China
  • Received:2019-07-11 Online:2019-09-08 Published:2019-09-08
  • Contact: Yu Zhancai E-mail:lzg6598@126.com

PDF

212

摘要： 转化生长因子-β（TGF-β）是TGF-β超家族中的一种多肽类细胞因子，TGF-β信号通路可调控细胞生物学活性，在肿瘤发生发展过程中发挥双向调节作用。该信号传导通路可通过诱导细胞过度增殖、影响肿瘤微环境、调节免疫逃避等引起卵巢癌发生、发展。以TGF-β为生物标志物的卵巢癌靶向治疗为改善患者预后提供了新的路径。

关键词: 卵巢肿瘤, 转化生长因子-β, 分子靶向治疗

Abstract: The transforming growth factor-β (TGF-β) is a polypeptide cytokine, belonging to the TGF-β  superfamily. TGF-β signaling pathway can regulate cell biological activity and play a bidirectional regulatory role in the development and progression of cancer. TGF-β signaling pathway can cause the occurrence and development of ovarian cancer through various processes including inducing cell excessive proliferation, influencing tumor microenvironment and regulating immune evasion. Targeted therapy with TGFβ as a biomarker for ovarian cancer provides a new way to improve the prognosis of patients.

Key words: Ovarian neoplasms, Transforming growth factor β, Molecular targeted therapy